Following the Supreme Court’s decision in Sandoz v Amgen, both drug makers have filed, in compliance with the Federal Circuit court’s order, supplemental briefs. These briefs state the parties’ opinions on the appropriate action to be taken after the Supreme Court remanded the case to the lower courts.
Following the Supreme Court’s recent decision in the case of Sandoz v Amgen, both drug makers this week filed supplemental briefs in compliance with a Federal Circuit court order. These briefs state the parties’ opinions on the appropriate action to be taken after the Supreme Court remanded the case to the lower courts.
In its brief, Amgen said that Sandoz’s refusal to provide its abbreviated Biologics License Application for its biosimilar filgrastim was a violation of the Biologics Price Competition and Innovation Act (BPCIA), and was therefore “unlawful” and “wrongful.” It stated that the failure of Sandoz to comply with the patent dance is sufficient to vacate the district court’s previous dismissal of Amgen’s claim against Sandoz under California’s laws concerning unfair competition. It also claimed that the BPCIA does not preempt any state law remedies for a failure to comply with the patent dance, because the BPCIA does not provide a remedy of its own for a failure to comply with its provisions. Furthermore, Amgen claims that Sandoz has waived any preemption defense in the past, so it should not be allowed to argue preemption now.
Sandoz, in its brief, said that the court should affirm the dismissal of Amgen’s claims under state laws, because, it claims, state laws are preempted by the BPCIA. “Allowing the 50 states to overlay their own disparate remedies onto the BPCIA’s complex procedural scheme would disrupt the careful balance struck by Congress,” Sandoz said. “As the Supreme Court recognized, Congress chose which remedies to provide and chose not to provide others.” Sandoz asked that the case be remanded directly to the district court rather than be made the subject of a separate appellate proceeding.
Ha Kung Wong, JD, told The Center for Biosimilars® in a recent interview, “[The Supreme Court] remanded the question to the Federal Circuit as to whether an injunction may be available under state law, and specifically whether an injunction for failure to provide the initial disclosures was available under California’s unfair competition law. That’s one question that was deliberately left unanswered by the Court in Sandoz.”
The issue of whether the BPCIA preempts remedies under state law could be informed by an amicus brief; as Big Molecule Watch reports, the United States is considering filing such a brief in the case to address the question of preemption. The court has extended the window for amicus brief filing until September 11, 2017.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.